All In Biotech

Drug Trial Radar · NCT02930005

Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders

A Pilot Open-label Trial of Pentosan Polysulfate Sodium and Meclofenamic Acid As Adjunctive Treatments in Patients With Psychotic Disorders

Last checked: Nov 19, 2026Latest source record: Mar 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

8

Actual

Start

Aug 7, 2015

Primary completion

Oct 6, 2016

Study completion Oct 6, 2016

Sponsor

Lead sponsor
The University of Texas Health Science Center, HoustonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 11, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the feasibility of administering meclofenamic acid or pentosan polysulfate sodium as an adjunctive treatment to patients diagnosed with a psychotic disorder. Half of participants will receive meclofenamic acid, while the other half will receive polysulfate sodium.

Conditions

  • Psychotic Disorders
  • Schizophrenia
  • Schizoaffective Disorder
  • Bipolar Disorder

Interventions

  • Meclofenamic acidDrug

  • Pentosan polysulfate sodiumDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Cognitive Function as Assessed by the NIH Toolbox Cognitive Test Battery (NCTB) Composite ScoreTime frame: baseline, 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The University of Texas Health Science Center at Houston

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.